Integra LifeSciences

Rank#6011

Market Cap1.18B

CountryUnited States

Summary

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

History

Integra LifeSciences was founded by Richard Caruso in 1989 after Caruso licensed Integra artificial skin technology from Harvard-MIT and acquired Colla-tec, a subsidiary of Marion Laboratories. The company became publicly traded under the NASDAQ ticker name IART.In 1996, Integra artificial skin was approved by the U.S. Food and Drug Administration. The artificial skin, manufactured and patented as Integra, is now used on patients with extensive burns. In 1999, the FDA approved Integra LifeSciences’ DuraGen, an absorbable implant used in neurosurgical and spinal procedures.In 2001, the company received FDA approval for Licox, a brain tissue oxygen and temperature monitor. Licox is used to treat patients in critical care, including those suffering from traumatic brain injuries.In 2002, the FDA approved the use of Integra Dermal Regeneration Template for reconstructive surgery of burn scars. In 2016, IDRT received premarket approval from the FDA for the treatment of diabetic foot ulcers.In 2018, Integra LifeSciences was included in Fortune’s list of Fastest Growing Companies.In 2021, Integra ranked #57 on Medical Design and Outsourcing’s list of largest medical technology companies in the world.

Mission

Integra Brand Promises Integra Promises to Limit Uncertainty by: Making everything you touch and do as simple as possible. Simplifying procedures and products to eliminate unnecessary steps, recognizing that time is your scarcest resource. Involving surgeons in creating better products and procedures because we believe surgery is a blend of art and science. Having the best-trained professionals dedicated to anticipating the needs of the busiest surgeons. Delivering our products when and where you need them, every time. Quickly replacing or repairing products, because minutes matter.

Vision

To be the leading innovator in medical technology.

References

https://en.wikipedia.org/wiki/Integra_LifeSciences

https://in.investing.com/equities/integra-lifescien

https://finance.yahoo.com/quote/IART/profile?p=IART

https://www.comparably.com/companies/integra-lifesciences/mission

https://www.crunchbase.com/organization/integra-lifesciences-holdings

https://sec.report/CIK/0000917520

https://companiesmarketcap.com/

https://www.integralife.com

Leadership team